T.J. Monberg , T. Kudling , B. Albieri , S. Pakola , E. Ellebaek , M. Donia , R.L. Eefsen , C. von Buchwald , C. Kistler , J.M. Santos , J. Clubb , L. Haybout , M.C.W. Westergaard , D.C.A. Quixabeira , E. Jirovec , R. Havunen , S. Sorsa , V. Cervera-Carrascon , A. Hemminki , I.M. Svane
{"title":"Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma","authors":"T.J. Monberg , T. Kudling , B. Albieri , S. Pakola , E. Ellebaek , M. Donia , R.L. Eefsen , C. von Buchwald , C. Kistler , J.M. Santos , J. Clubb , L. Haybout , M.C.W. Westergaard , D.C.A. Quixabeira , E. Jirovec , R. Havunen , S. Sorsa , V. Cervera-Carrascon , A. Hemminki , I.M. Svane","doi":"10.1016/j.iotech.2024.100726","DOIUrl":"10.1016/j.iotech.2024.100726","url":null,"abstract":"<div><h3>Background</h3><div>Despite significant advancements in the treatment of malignant melanoma, metastatic mucosal melanoma remains a therapeutic challenge due to its complex pathogenesis, distinct pathological characteristics, and limited response to immunotherapy. Combining different immunotherapeutic approaches offers a potential strategy to address these challenges. Tumor-infiltrating lymphocyte (TIL) therapy and oncolytic virus therapy represent promising treatment modalities that may synergize with each other.</div></div><div><h3>Patient and methods</h3><div>We present a case of a 48-year-old woman with metastatic sinonasal mucosal melanoma who achieved a durable complete pathological response following treatment with multiple injections of the oncolytic virus TILT-123 (igrelimogene litadenorepvec) and a single infusion of TILs, without preconditioning chemotherapy or postconditioning interleukin-2.</div></div><div><h3>Results</h3><div>Immunohistochemical analysis and single-cell sequencing revealed interesting alterations in injected and noninjected tumors as well as in peripheral blood, during the treatment course, suggesting that TILT-123 facilitated TIL engraftment into the tumor, ultimately leading to a complete response.</div></div><div><h3>Conclusions</h3><div>This case underscores the potential of combined immunotherapeutic approaches as a promising strategy for patients with metastatic mucosal melanoma.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100726"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Ma, K. Hu, R. Karatill, R. Williams, J. Hayre, S. Srivastava, S. Cordoba, S. Onuoha
{"title":"57P SENDER™ directed LNP delivery of mRNA for in situ generation of highly potent CAR T cells","authors":"B. Ma, K. Hu, R. Karatill, R. Williams, J. Hayre, S. Srivastava, S. Cordoba, S. Onuoha","doi":"10.1016/j.iotech.2024.100868","DOIUrl":"10.1016/j.iotech.2024.100868","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100868"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143134576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Ziogas , H. Linardou , A. Charpidou , A. Koumarianou , G. Mountzios , P. Kosmidis , C. Christodoulou , D. Mavroudis , A.N. Christopoulou , I. Korantzis , S. Baka , M. Vaslamatzis , I. Athanasiadis , A. Koutras , D. Mauri , A. Kotsakis , A. Visvikis , F. Spanoudi , T. Tsichritzis , K. Syrigos
{"title":"94P Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first-line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study","authors":"D. Ziogas , H. Linardou , A. Charpidou , A. Koumarianou , G. Mountzios , P. Kosmidis , C. Christodoulou , D. Mavroudis , A.N. Christopoulou , I. Korantzis , S. Baka , M. Vaslamatzis , I. Athanasiadis , A. Koutras , D. Mauri , A. Kotsakis , A. Visvikis , F. Spanoudi , T. Tsichritzis , K. Syrigos","doi":"10.1016/j.iotech.2024.100837","DOIUrl":"10.1016/j.iotech.2024.100837","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100837"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E.Y. Baitei , A. Bzura , M. Zhang , C. Poile , A. Branson , A. King , S. Barber , C. Brookes , J. Dzialo , A. Greystoke , L. Nolan , M. Dungey , M. Scotland , A. Bajaj , P. Wells-Jordan , C. Richards , A. Thomas , M.G. Krebs , D.A. Fennell
B.V. Popescu , N. Taris , A. Bendjama , L. Bender , C. Pflumio , C. Fischbach , M. Kalish-Weindling , C. Mathelin , T. Petit , X. Pivot
{"title":"19P Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab","authors":"B.V. Popescu , N. Taris , A. Bendjama , L. Bender , C. Pflumio , C. Fischbach , M. Kalish-Weindling , C. Mathelin , T. Petit , X. Pivot","doi":"10.1016/j.iotech.2024.100902","DOIUrl":"10.1016/j.iotech.2024.100902","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100902"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}